The Potential Impact of GLP-1 Receptor Agonists on Exacerbation Risk in Patients with COPD and Type 2 Diabetes: A Real-World Population-Based Observational Study
{{output}}
Introduction: There is limited evidence on the impact of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in patients with chronic obstructive pulmonary disease (COPD). ... ...
